Latest news with #CentralNervous
&w=3840&q=100)
Business Standard
13-05-2025
- Business
- Business Standard
Smallcap stock surges 15%, hits record high today; what's behind the rally?
Suven Life Sciences share price today: Shares of Suven Life Sciences (Suven) hit a record high of ₹175, surging 15 per cent on the BSE in Tuesday's intraday trade amid heavy volumes, in an otherwise weak market. The stock price of the smallcap company surpassed its previous high of ₹169, which it touched on September 18, 2024. In past one week, the market price of Suven Life share appreciated 37 per cent after the company announced a fundraising plan by way of issue of equity shares / warrants / any convertible securities / any other securities, through one or more of the permissible modes including but not limited to a qualified institutions placement, preferential allotment etc. At 01:34 PM, Suven share price was quoting 10.5 per cent higher at ₹168.80, as compared to 1.5 per cent decline in the BSE Sensex. Average trading volume on the counter jumped six-fold today with 7.3 million equity shares, cumulatively, changing hands on the NSE and BSE till the time of writing this report. The board of directors of Suven Life Sciences, today, approved fund raising of ₹857.64 crore through fully convertible warrants on preferential basis to continue the funding of R&D, Clinical Development programmes, general corporate purposes, and apex for creating a new R&D facility. The board of directors of Suven Life Sciences, in its meeting on May 13, 2025, approved the issue of 64 million warrants convertible into equity shares of the company on preferential basis to promoter group entity and to certain non-promoter persons/entities at a price of ₹134 per warrant aggregating up to ₹857.64 crore. The board approved allotment of 31.77 million warrants to promoter group entity i.e. Jasti Property and Equity Holdings Private Limited (In its capacity as sole trustee of Jasti Family Trust). The board also approved allotment of warrants to Quant Mutual Fund (4.7 million), Abakkus Diversified Alpha Fund (2.99 million), 3P India Equity Fund 1 (3.36 million), Nilesh Kishor Shah (1.2 million) and Ketan Chhotalal Seth (2 million). Suven Life Q4 results 2025 Suven Life reported a consolidated loss of ₹44.51 crore for the quarter ended March 2025 (Q4FY25), as against a loss of ₹26.74 crore in the year-ago quarter. Revenue for the quarter stood at ₹2.69 crore, as against ₹6.67 crore in Q4FY24. The company said the statement of operations includes financials of Suven Neurosciences, Inc., a Delaware Company, wholly owned subsidiary (WOS) of Suven, involved in clinical development programs of the Company. Suven continues its R&D programs focused on Central Nervous System (CNS) disease disorders and granted 20 patents during the period covering countries Brazil, Eurasia, Europe, Hong Kong, India, Israel, Japan, Macao, Mexico, New Zealand, Sri Lanka, South Africa and USA Clinical development pipeline SUVN-502 (Masupirdine) – Ongoing phase 3 study for Agitation and Aggression in Alzheimer's type dementias in North America and Europe; Enrolling patients in sites in US and Europe. Expected completion by end of FY26. SUVN-G3031 (Samelisant) – Preparing to start Phase 3 clinical study for treatment of EDS in Narcolepsy in Q2FY26. SUVN-911 (Ropanicant) – Phase 2A open label study for Major Depressive Disorder in the USA successfully completed. The initiated Phase 2B clinical study is in Q1FY26. SUVN-D4010 (Usmarapride) – Planning for Phase 2 double blind study for the treatment of Cognition during FY26. SUVN-I6107 – Phase 1 study initiated during FY25 is continuing for establishing safety and pharmacokinetics of the molecule. About Suven Life Sciences Suven, a Biopharmaceutical company, is engaged in Drug Discovery and Development of New Chemical Entities (NCEs) in Central Nervous System (CNS) disorders targeting unmet medical needs, globally. The company has a portfolio of advanced stage clinical candidates and research programs that are designed for CNS disorders such as Alzheimer's disease (AD), sleep disorders, major depressive disorders (MDD), Parkinson's disease (PD), Schizophrenia, Pain disorders, and Gastrointestinal disorders.
Time of India
05-05-2025
- Health
- Time of India
AUTOIMMUNE CNS DISORDERS
Autoimmune Central Nervous System (CNS) disorders develop when the body's immune system mistakenly attacks its healthy brain cells/ neurons, leading to inflammation of the brain. This may be associated with antibodies to proteins located either on the surface of nerve cells or within nerve cells. Antibody-mediated CNS disorders are increasingly recognized as neurologic disorders that can be severe and even life-threatening but with the potential for reversibility with appropriate treatment. The expanding spectrum of newly identified autoantibodies and associated clinical syndromes (ranging from autoimmune encephalitis to CNS demyelination ) has increased diagnostic precision and allowed critical reinterpretation of non-specific neurological syndromes historically associated with systemic disorders. Detection of neural autoantibodies with accurate laboratory assays in patients with compatible clinical-MRI phenotypes allows a definite diagnosis of antibody-mediated CNS disorders, with important therapeutic and prognostic implications. A large spectrum of diseases is covered in these disorders depending on the target site against which Antibodies develop. These include Limbic encephalitis, Morvan syndrome, Facio-brachial dystonic seizures, Opsoclonus-myoclonus syndrome, Demyelinating Syndromes, Acute disseminated encephalomyelitis, Optic neuritis, anti-MOG-associated encephalitis – to name the few. Other autoimmune syndromes may be associated with various cancers. This group of conditions may have various neurologic and/or psychiatric symptoms. Symptoms may start with psychiatric manifestations followed by symptoms may include psychosis, aggression, inappropriate sexual behaviours, panic attacks, compulsive behaviours, euphoria, or fear. The disorders may start with flu-like conditions & develop further into neurological manifestations. Neurologic symptoms may include impaired memory and cognition, abnormal movements, seizures, and/or problems with balance, speech, or vision. There are two major requirements for a correct diagnosis of antibody-mediated CNS disorder to be made: (1)a reliable identification of one or more specific neural autoantibodies; and (2)a compatible clinical-MRI phenotype. Over the years, there has been an ongoing discovery of newer antibodies against various proteins. NMDA, LG -i1, CASPR-2, AMPA, GABA A, GABA B, GAD65 DPPx, IGNOL-5 causing Limbic antibodies and MOG autoantibodies cause Optic neuritis, Acute disseminated encephalomyelitis & Myelitis lesions. Certain neural autoantibodies are strongly associated with specific types of cancer. Sophisticated technology which includes Neural Autoantibody Testing by Indirect Cell-Based Immunofluorescence assay, immunoblot assay, ELISA, and Cell cultures allows for accurate laboratory diagnosis. These tests can be performed on Blood & CSF (cerebrospinal fluid). Although autoimmune CNS disorders are often treatment-responsive, they can lead to serious complications if left untreated or if there is a delay in treatment. Timely diagnosis and treatment, therefore, becomes important to avoid complications of the disease. Treatment may include Immunotherapy (e.g., plasmapheresis, intravenous Immunoglobulin, and corticosteroids) and tumour resection if the disease is associated with the tumour. Patient education is necessary to understand the etiology, acute and chronic clinical progression of the condition, and its probable association with underlying malignancy. They should be educated about the variable course of the disease, which may lead to a delay in diagnosis. Furthermore, patients should be encouraged to follow up after hospital discharge with their respective neurologist /oncologist due to concerns about relapse and screening for malignancy. This article is written by Dr. Geeta Chopra, Chief of Lab – North India Operations, Metropolis Healthcare Limited. (DISCLAIMER: The views expressed are solely of the author and does not necessarily subscribe to it. shall not be responsible for any damage caused to any person/organisation directly or indirectly)
Yahoo
28-04-2025
- Business
- Yahoo
Shape Therapeutics Announces Multiple Oral and Poster Presentations at the American Society of Gene & Cell Therapy 28th Annual Meeting
Data support potential of innovative gene therapy using novel RNA editing, paired with targeted delivery and scalable manufacturing platforms SEATTLE, April 28, 2025 (GLOBE NEWSWIRE) -- Shape Therapeutics, a leader in RNA-based gene therapy, today announced the acceptance of multiple abstracts, including two oral presentations, at the upcoming 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) that will take place May 13-17, 2025, in New Orleans, Louisiana. 'We look forward to sharing a bolus of data at this year's ASGCT as it builds on our scientific body of evidence that support the development of our programmable RNA medicines to shape the future of gene therapy through precise RNA editing, targeted delivery and scalable manufacturing,' stated David Huss, Ph.D., CSO and acting CEO of Shape Therapeutics. Details of the presentations are below: Presentation Title: Programmable RNA Editing Enables Precise Protein Modulation in the Central Nervous SystemPresenter: Dr. Alison VanSchoiack, Shape TherapeuticsSession Date and Time: Wednesday, May 14, 2025, 5:30-7:00pm CTSession Title: Wednesday Poster ReceptionSession Room: Poster Hall I2 Presentation Title: Comprehensive Evaluation of TruStable™ vs Transient Production Systems of AAV Vector ManufacturingPresenter: Ken Prentice, Shape TherapeuticsSession Date and Time: Thursday, May 15, 2025, 5:30-7:00pm CTSession Title: Thursday Poster ReceptionSession Room: Poster Hall I2 Oral Presentation Title: Systemically Delivered AAV5-Based Capsid Variants Enable up to 88% Targeted RNA Editing in Primate Brain Presenter: Dr. Rick Sullivan, Shape TherapeuticsSession Date and Time: Friday, May 16, 2025, 1:45-2:00pm CTSession Title: AAV Gene Transfer (B): Ocular, Neurological & Immune Cell SystemsSession Room: NOLA Theater A Oral Presentation Title: Mechanistic Insights Enhance Multi-Serotype Production in the TruStable™ AAV Producer Cell LinePresenter: Dr. Sandhya Pande, Shape TherapeuticsSession Date and Time: Friday, May 16, 2025, 5:00-5:15pm CT Session Title: AAV Vector Manufacturing: Plasmids & Cell Line DevelopmentSession Room: NOLA Theater C About Shape Therapeutics ShapeTX is an AI-driven genomic medicines company focused on creating curative and transformative medicines through its programmable RNA editing technology. By focusing on three differentiated pillars of value, ShapeTX utilizes its RNAfix® technology, targeted delivery system and TruStable™ manufacturing platform to advance a strong internal pipeline of RNA therapeutics across a wide range of diseases, including ABCA4-related diseases and neurological disorders. You can find us at and on LinkedIn and X. Investor Contact:Anne Marie FieldsPrecision Media Contact:info@ in to access your portfolio
